Clinical trial · Observational
Efficacy and Safety of the Anti- COVID-19 Vaccin in Clinical Hematology Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that was first reported in December 2019 in Wuhan, China. Infection with this new coronavirus called SARS-CoV-2 can lead to fatal pneumonia associated with high rates of hospitalization in intensive care units (ICU). Hospitalized patients with hematologic malignancies have a higher mortality rate than patients without hematologic malignancies (62% vs. 8%). The severity of Covid-19 may be related to their treatment, in particular anti-CD20 used in B lymphoid hemopathies. In fact, anti-CD20 antibodies induce rapid and prolonged depletion of B cells, but they are necessary for development. humoral immune responses. But currently, no immunogenicity data are known for patients with hemopathy or in those on anti-lymphocyte immunochemotherapy.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Covid19 | — | UNRESOLVED | — |
| Hematologic Malignancy | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
| Vaccine Response Impaired | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Patients with hemopathy | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- humoral response after COVID19 vaccination
- timeFrame
- 1 month after vaccination
- description
- SARS-CoV-2 Trimeric S IgG titers (BAU/ml)
Secondary outcomes (7)
- measure
- humoral response after COVID19 vaccination
- timeFrame
- before first dose vaccination
- description
- SARS-CoV-2 Trimeric S IgG titers (BAU/ml)
- measure
- humoral response after COVID19 vaccination
- timeFrame
- before second dose vaccination
- description
- SARS-CoV-2 Trimeric S IgG titers (BAU/ml)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Benign or malignant hemopathy * With priority vaccination indication * Having benefited from anti-covid-19 mRNA vaccination Exclusion Criteria: * Patients under legal protection * Palliative care patients * History of known Covid-19 disease (\<1 year)
References
Publications (1)
- DERIVEDGueguen M, Khatchatourian L, Loheac C, Dorval I, Mercier M, Le Calloch R, Mahe K, Rizcallah MJ, Hutin P, Fangous MS, Saidani N, Le Clech L. The humoral response of mRNA COVID-19 vaccine in hematological diseases: The HEMVACO study. Infect Dis Now. 2022 Aug;52(5):280-285. doi: 10.1016/j.idnow.2022.05.008. Epub 2022 Jun 3. PMID 35667558